skip to Main Content
  • This page as PDF
July 22, 2020 12:30 - 1:30 PM ET

Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics 


Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access. 

With hundreds of vaccine and therapeutic candidates in the pipeline, planning ahead for patient access is vital. This uncharted territory provokes important questions about regulatory pathways, pricing, government procurement, coverage, access, distribution, and more.  Avalere experts explored these questions and tipping pointsas well as the necessary market access strategies. 

Key Topics

  • FDA regulatory considerations and downstream implications 
  • Coverage and access challenges 
  • Pricing, procurement, and distributionscenarios 
  • Potential 2020 election impacts on the COVID-19 response


Elizabeth Carpenter , Head of Advisory Services

Elizabeth specializes in policy, particularly in the implementation of the Affordable Care Act (ACA), trends in commercial insurance, drug pricing policy, and the impact of politics on the policy landscape.

Kelly L. George , Associate Principal, Commercialization & Regulatory Strategy


Richard Hughes IV , Managing Director

Richard Hughes IV leads Avalere’s vaccines team, which supports clients with vaccine policy, market access and evidence strategies.

John C. Neal , Managing Director, Commercialization & Regulatory Strategy

John C. Neal partners with pharmaceutical and biotech clients to develop market access assessments and launch strategies designed to ensure successful commercialization of assets.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top